Yüklüyor......
Response to Imatinib therapy is inferior for e13a2 BCR-ABL1 transcript type in comparison to e14a2 transcript type in chronic myeloid leukaemia
BACKGROUND: The BCR-ABL1 fusion gene underlying the pathogenesis of CML can arise from a variety of breakpoints. The e13a2 and e14a2 transcripts formed by breakpoints occurring around exon 13 and exon 14 of the BCR gene respectively are the most common. METHODS: We undertook a retrospective audit us...
Kaydedildi:
| Yayımlandı: | BMC Hematol |
|---|---|
| Asıl Yazarlar: | , , , , , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
BioMed Central
2019
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC6498698/ https://ncbi.nlm.nih.gov/pubmed/31073408 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s12878-019-0139-2 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|